Abstract
OA 16.04 Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have